2 weeks Ago By ABMN Staff
Dai ichi Life Insurance Company Ltd acquired a new stake in Royalty Pharma plc ( NASDAQ:RPRX – Free Report ) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 94,066 shares of the biopharmaceutical company’s stock, valued at approximately $2,481,000. Other large investors have also added to or reduced their stakes in the company.
Swedbank AB acquired a new position in Royalty Pharma in the 1st quarter valued at approximately $251,461,000. Norges Bank acquired a new stake in Royalty Pharma in the fourth quarter valued at $119,740,000. New South Capital Management Inc.
bought a new position in Royalty Pharma during the 1st quarter worth $44,384,000. ADAR1 Capital Management LLC acquired a new position in Royalty Pharma during the 4th quarter worth about $37,130,000. Finally, Patient Capital Management LLC bought a new stake in shares of Royalty Pharma in the 4th quarter valued at about $35,247,000.
Institutional investors own 54.35% of the company’s stock. Wall Street Analysts Forecast Growth RPRX has been the topic of a number of recent analyst reports.
The Goldman Sachs Group lifted their price objective on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th.
UBS Group lowered shares of Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective on the stock. in a research note on Monday, June 3rd.
Morgan Stanley lifted their target price on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, July 11th.
Finally, StockNews.com cut shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research report on Monday, September 9th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company.
According to MarketBeat, Royalty Pharma has an average rating of “Moderate Buy” and an average price target of $42.00. Royalty Pharma Trading Up 0.
6 % NASDAQ:RPRX opened at $27.72 on Monday. The firm has a fifty day simple moving average of $27.
80 and a two-hundred day simple moving average of $28.04. Royalty Pharma plc has a 12 month low of $25.
20 and a 12 month high of $31.66. The stock has a market capitalization of $16.
45 billion, a price-to-earnings ratio of 20.69, a PEG ratio of 4.06 and a beta of 0.
46. The company has a current ratio of 9.35, a quick ratio of 9.
35 and a debt-to-equity ratio of 0.78. Royalty Pharma ( NASDAQ:RPRX – Get Free Report ) last issued its earnings results on Thursday, August 8th.
The biopharmaceutical company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.
01. The business had revenue of $537.00 million during the quarter, compared to analyst estimates of $600.
83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.
08%. During the same period in the previous year, the company posted $0.85 EPS.
Analysts expect that Royalty Pharma plc will post 4.04 EPS for the current fiscal year. Royalty Pharma Dividend Announcement The company also recently announced a quarterly dividend, which was paid on Friday, September 13th.
Investors of record on Friday, August 16th were issued a $0.21 dividend. This represents a $0.
84 dividend on an annualized basis and a dividend yield of 3.03%. The ex-dividend date of this dividend was Friday, August 16th.
Royalty Pharma’s dividend payout ratio is currently 62.69%. About Royalty Pharma ( Free Report ) Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Recommended Stories Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Royalty Pharma plc ( NASDAQ:RPRX – Free Report ). Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter .
.
